– Four posters highlight TERLIVAZ research on the potential impact of dosing and outcomes in key subpopulations of adults with HRS with rapid reduction in kidney function1 – DUBLIN, Oct. 30, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced...
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Seaking AlphaSeeking Alpha / Seaking Alpha 15 hours ago 1 Views
Comments